Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) Research & Development (2016 - 2026)

Sanofi's Research & Development history spans 16 years, with the latest figure at -$2.0 billion for Q1 2026.

  • On a quarterly basis, Research & Development fell 7.54% to -$2.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$19.8 billion, a 46.03% decrease, with the full-year FY2025 number at $9.1 billion, up 15.53% from a year prior.
  • Research & Development hit -$2.0 billion in Q1 2026 for Sanofi, up from -$9.1 billion in the prior quarter.
  • Over the last five years, Research & Development for SNY hit a ceiling of -$1.7 billion in Q1 2022 and a floor of -$9.1 billion in Q4 2025.
  • Historically, Research & Development has averaged -$3.5 billion across 5 years, with a median of -$1.9 billion in 2025.
  • Biggest five-year swings in Research & Development: plummeted 277.33% in 2022 and later dropped 0.33% in 2023.
  • Tracing SNY's Research & Development over 5 years: stood at -$6.8 billion in 2022, then dropped by 2.33% to -$7.0 billion in 2023, then decreased by 12.86% to -$7.9 billion in 2024, then dropped by 15.53% to -$9.1 billion in 2025, then skyrocketed by 77.59% to -$2.0 billion in 2026.
  • Business Quant data shows Research & Development for SNY at -$2.0 billion in Q1 2026, -$9.1 billion in Q4 2025, and -$6.5 billion in Q3 2025.